Jones Financial Companies Lllp Purchases 971 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Jones Financial Companies Lllp boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 29.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,228 shares of the company’s stock after buying an additional 971 shares during the quarter. Jones Financial Companies Lllp’s holdings in Structure Therapeutics were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock worth $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC raised its holdings in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GPCR. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $21.05 on Friday. Structure Therapeutics Inc. has a 1-year low of $19.39 and a 1-year high of $62.74. The firm’s 50-day moving average price is $25.31 and its 200-day moving average price is $32.38. The company has a market capitalization of $1.21 billion, a PE ratio of -28.45 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.